By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Pepiniere Sante Cochin
29 rue du Faubourg Saint Jacques
Paris    75014  France
Phone: 01-55-426200 Fax: 01-55-426201


Company News
PHARNEXT Announces Initiation Of Phase III Extension Study PLEO-CMT-FU Of PXT3003 For Treatment Of Charcot-Marie-Tooth Disease Type 1A 3/16/2017 11:06:12 AM
PHARNEXT Announces R&D Agreement With Galapagos (GLPG.BR) To Generate A New Pipeline Of Synergistic Drug Combinations 3/9/2017 10:03:06 AM
PHARNEXT To Present At 2017 BIO CEO & Investor Conference 2/7/2017 7:13:38 AM
PHARNEXT Announces Findings Evaluating Charcot-Marie-Tooth Neuropathy Score 2/2/2017 6:29:56 AM
PHARNEXT To Attend January Investor Conferences 1/4/2017 8:46:32 AM
PHARNEXT Completes Patient Enrollment In International Pivotal Phase 3 Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 12/20/2016 12:58:14 PM
PHARNEXT Presents Positive Exploratory Phase 2 Data From PXT864 At The 9th Clinical Trials On Alzheimer’s Disease (CTAD) Conference In San Diego, United States 12/13/2016 11:20:45 AM
PHARNEXT Announces That The Data Safety Monitoring Boardrecommends Continuing The Ongoing Phase 3 Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 11/17/2016 11:35:26 AM
PHARNEXT Announces Support Of The First Patient-Centered Charcot-Marie-Tooth Summit Organized By The Hereditary Neuropathy Foundation 10/4/2016 12:30:46 PM
PHARNEXT Confirms Its Continuous Support Of The Hereditary Neuropathy Foundation To Increase Global Awareness Of Charcot-Marie-Tooth Disease 9/15/2016 11:39:01 AM